19.17
0.17 (0.89%)
| Penutupan Terdahulu | 19.00 |
| Buka | 19.19 |
| Jumlah Dagangan | 1,169,546 |
| Purata Dagangan (3B) | 757,052 |
| Modal Pasaran | 1,317,230,208 |
| Harga / Jualan (P/S) | 6.50 |
| Harga / Buku (P/B) | 2.25 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 25 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | -191.56% |
| Margin Operasi (TTM) | -58.89% |
| EPS Cair (TTM) | -4.79 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 196.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.26% |
| Nisbah Semasa (MRQ) | 4.17 |
| Aliran Tunai Operasi (OCF TTM) | -258.30 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -170.11 M |
| Pulangan Atas Aset (ROA TTM) | -20.07% |
| Pulangan Atas Ekuiti (ROE TTM) | -59.16% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Arvinas, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -4.0 |
| Purata | 0.00 |
|
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 7.21% |
| % Dimiliki oleh Institusi | 108.73% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| New Leaf Venture Partners, L.L.C. | 30 Sep 2024 | 1,434,721 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 88.00 (BMO Capital, 359.05%) | Beli |
| Median | 71.00 (270.37%) | |
| Rendah | 40.00 (Oppenheimer, 108.66%) | Beli |
| Purata | 67.50 (252.11%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 23.71 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 11 Dec 2024 | 87.00 (353.83%) | Beli | 22.54 |
| 31 Oct 2024 | 87.00 (353.83%) | Beli | 26.43 | |
| BMO Capital | 20 Nov 2024 | 88.00 (359.05%) | Beli | 22.69 |
| Stephens & Co. | 18 Nov 2024 | 55.00 (186.91%) | Beli | 23.19 |
| Oppenheimer | 31 Oct 2024 | 40.00 (108.66%) | Beli | 26.43 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 10 Dec 2024 | Pengumuman | Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium |
| 27 Nov 2024 | Pengumuman | Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference |
| 25 Nov 2024 | Pengumuman | Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium |
| 04 Nov 2024 | Pengumuman | Arvinas to Participate in Upcoming Investor Conferences |
| 30 Oct 2024 | Pengumuman | Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
| 22 Oct 2024 | Pengumuman | Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day |
| 21 Oct 2024 | Pengumuman | Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |